Immune-based therapeutics for pediatric cancer

Bibliography

• Wayne AS, Reaman GH, Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst 2008;100(18):1271-3
   PubMed Web of Science ®Google Scholar
• Cullen KV, Davey RA, Davey MW. Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leuk Res 2001;25(1):69-75
   PubMed Web of Science ®Google Scholar
• Giavazzi RR, Bucana CCD, Hart IIR. Correlation of tumor growth inhibitory activity of macrophages exposed to adriamycin and adriamycin sensitivity of the target tumor cells. J Natl Cancer Inst 1984;73(2):447-55
   PubMed Web of Science ®Google Scholar
• Kontny HU, Lehrnbecher TM, Chanock SJ, Mackall CL. Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res 1998;58(24):5842-9
   PubMed Web of Science ®Google Scholar
• Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22(6):1136-51
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22(1):329-60
   PubMedGoogle Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15
   PubMed Web of Science ®Google Scholar
• Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Exp Opin Biol Ther 2008;8(7):951-68
   PubMed Web of Science ®Google Scholar
• Capitini CM, Cooper LJN, Egeler RM, Highlights of the First International “Immunotherapy in Pediatric Oncology: Progress and Challenges” Meeting. J Pediatr Hematol Oncol 2009;31(4):227-44
   PubMed Web of Science ®Google Scholar
• Rassam S, Katz F, Chessells J, Morgan G. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect? Bone Marrow Transplant 1993;11(3):247-50
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62
   PubMed Web of Science ®Google Scholar
• Passweg JJR, Tiberghien PP, Cahn JJY, Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998;21(2):153-8
   PubMed Web of Science ®Google Scholar
• Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41(5):483-93
   PubMed Web of Science ®Google Scholar
• Maraninchi DD, Gluckman EE, Blaise DD, Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987;2(8552):175-8
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86(5):2041-50
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Weiden PL, Storb R, Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia published erratum appears in Blood 1989;74(3):1180. Blood 1989;73(6):1720-8
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Henze GHR, Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009;27(3):377-84
   PubMed Web of Science ®Google Scholar
• Krejci O, van der Velden VHJ, Bader P, Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003;32(8):849-51
   PubMed Web of Science ®Google Scholar
• Collins RH, Shpilberg O, Drobyski WR, Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15(2):433-44
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Hermans J, Apperley J, Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995;86(2):813-8
   PubMed Web of Science ®Google Scholar
• Zecca M, Prete A, Rondelli R, Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100(4):1192-200
   PubMed Web of Science ®Google Scholar
• Vago L, Perna S, Zanussi M, Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009;361(5):478-88
   PubMed Web of Science ®Google Scholar
• Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98(12):3192-204
   PubMed Web of Science ®Google Scholar
• Sierra J, Perez WS, Rozman C, Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002;100(6):1997-2004
   PubMed Web of Science ®Google Scholar
• Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008;41(5):473-81
   PubMed Web of Science ®Google Scholar
• Green A, Clarke E, Hunt L, Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. Blood 1999;94(7):2236-46
   PubMed Web of Science ®Google Scholar
• Bonnanomi S, Connor P, Webb D, Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy. Bone Marrow Transplant 2008;42(4):253-7
   PubMed Web of Science ®Google Scholar
• Cross NC, Hughes TP, Feng L, Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993;84(1):67-74
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong ASM, Savani BN, Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007;110(6):1924-32
   PubMed Web of Science ®Google Scholar
• Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology 2003;2003(1):331-49
   Google Scholar
• Terme M, Ullrich E, Delahaye NF, Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008;9(5):486-94
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9(5):495-502
   PubMed Web of Science ®Google Scholar
• Koh CY, Blazar BR, George T, Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001;97(10):3132-7
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097-100
   PubMed Web of Science ®Google Scholar
• Davies SM, Ruggieri L, DeFor T, Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002;100(10):3825-7
   PubMed Web of Science ®Google Scholar
• Ruggeri LL, Mancusi AA, Burchielli EE, Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007;19(2):142-7
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299-308
   PubMed Web of Science ®Google Scholar
• Rosenberg SSA, White DDE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19(1):81-4
   Web of Science ®Google Scholar
• Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994;11(3):281-92
   PubMed Web of Science ®Google Scholar
• Mackall CL, Fleisher TA, Brown MR, Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332(3):143-9
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009;27(18S):2
   PubMedGoogle Scholar
• Celestia SH, Paul FS, Eric JS, Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-9
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Leen AM, Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110(8):2838-45
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61(23):8513-9
   PubMed Web of Science ®Google Scholar
• Geiger J, Hutchinson RR, Hohenkirk LL, Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000;356(9236):1163-5
   PubMed Web of Science ®Google Scholar
• Bowman L, Grossmann M, Rill D, IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998;92(6):1941-9
   PubMed Web of Science ®Google Scholar
• Rousseau RF, Haight AE, Hirschmann-Jax C, Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101(5):1718-26
   PubMed Web of Science ®Google Scholar
• Russell HV, Strother D, Mei Z, Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. Journal of Immunotherapy 2007;30(2):227-33
   PubMed Web of Science ®Google Scholar
• Simon RM, Steinberg SM, Hamilton M, Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001;19(6):1848-54
   PubMed Web of Science ®Google Scholar
• Mackall CL, Rhee EH, Read EJ, A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008;14(15):4850-8
   PubMed Web of Science ®Google Scholar
• Merchant M, Melchionda F, Sinha M, Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother 2007;56(7):1037-46
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69(9):4010-7
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Teng MWL, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005;5(12):928-40
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21(2):215-23
   PubMed Web of Science ®Google Scholar
• Park JR, Digiusto DL, Slovak M, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15(4):825-33
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70
   PubMed Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16(6):2169-80
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Cheung N-KV. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19(22):4189-94
   PubMed Web of Science ®Google Scholar
• Osenga KL, Hank JA, Albertini MR, A Phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12(6):1750-9
   PubMed Web of Science ®Google Scholar
• Modak S, Cheung N-K. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007;25(1):67-77
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Sondel PM, Krailo MD, Phase I Study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) With granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group study. J Clin Oncol 2000;18(24):4077-85
   PubMed Web of Science ®Google Scholar
• Schusterman S, London W, Gillies S, Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children's Oncology Group (COG) phase II study. J Clin Oncol 2008;26(20 Suppl): abstract 3002
   Google Scholar
• Cheung NK, Kushner BH, Cheung IY, Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16(9):3053-60
   PubMed Web of Science ®Google Scholar
• Yu A, Gilman A, Ozkaynak M, A Phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. J Clin Oncol 2009;27(15s): abstract 10067z
   Google Scholar
• Kramer K, Humm JL, Souweidane MM, Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-ommaya 131-I-3F8. J Clin Oncol 2007;25(34):5465-70
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G, Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17(9):2781-8
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Hattinger CM, Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41(9):1349-61
   PubMed Web of Science ®Google Scholar
• Rehwald U, Schulz H, Reiser M, Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101(2):420-4
   PubMed Web of Science ®Google Scholar
• Ekstrand BC, Lucas JB, Horwitz SM, Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101(11):4285-9
   PubMed Web of Science ®Google Scholar
• Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther 2009;9(2):231-41
   PubMed Web of Science ®Google Scholar
• David HL. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008;222(1):277-86
   PubMedGoogle Scholar
• Benesch MM, Windelberg MM, Sauseng WW, Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008;19(4):807-13
   PubMed Web of Science ®Google Scholar
• Bender JLG, Adamson PC, Reid JM, Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008;26(3):399-405
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Houghton PJ, Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(6):1190-7
   PubMed Web of Science ®Google Scholar
• Plummer R, Attard G, Pacey S, Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13(20):6187-94
   PubMed Web of Science ®Google Scholar
• Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol 2000;27(6 Suppl 12):30-6
   PubMed Web of Science ®Google Scholar
• Cooney-Qualter E, Krailo M, Angiolillo A, A Phase I Study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non Hodgkin's lymphoma: a Children's Oncology Group Study. Clin Cancer Res 2007;13(18):5652s-60
   PubMed Web of Science ®Google Scholar
• Schnell R, Borchmann P, Staak JO, Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14(5):729-36
   PubMed Web of Science ®Google Scholar
• Wayne A, Kreitman R, Pastan I. Monoclonal antibodies and immunotoxins as new therapeutic agents for childhood acute lymphoblastic leukemia in American Society of Clinical Oncology 2007 Educational Book. Alexandria, VA: ASM; 2007. p. 596-601
   Google Scholar
• Aplenc R, Alonzo TA, Gerbing RB, Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol 2008;26(14):2390-3295
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Sande J, Lange B, Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005;106(4):1183-8
   PubMed Web of Science ®Google Scholar
• Zwaan C, Reinhardt D, Jurgens H, Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003;17(2):468-70
   PubMed Web of Science ®Google Scholar
• Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007;61(6):299-305
   PubMed Web of Science ®Google Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13(5):552-9
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Yunis C, Harrison LI, First in human Phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13(23):7119-25
   PubMed Web of Science ®Google Scholar
• Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther 2008;8(2):151-9
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children's Oncology Group. J Clin Oncol 2008;26(4):633-8
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8(1):59-73
   PubMed Web of Science ®Google Scholar
• Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 2008;27(2):200-7
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2007;15(1):3-12
   PubMed Web of Science ®Google Scholar
• Riuzzi F, Sorci G, Donato R. RAGE Expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol 2007;171(3):947-61
   PubMed Web of Science ®Google Scholar
• Motohashi S, Ishikawa A, Ishikawa E, A Phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006;12(20):6079-86
   PubMed Web of Science ®Google Scholar
• Ishikawa A, Motohashi S, Ishikawa E, A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005;11(5):1910-7
   PubMed Web of Science ®Google Scholar
• Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9(1):28-38
   PubMed Web of Science ®Google Scholar
• Bennouna J, Bompas E, Neidhardt EM, Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57(11):1599-609
   PubMed Web of Science ®Google Scholar
• Roper M, Smith MA, Sondel PM, A Phase I study of interleukin-2 in children with cancer. J Pediatr Hematol Oncol 1992;14(4):305-11
   Web of Science ®Google Scholar
• Bauer M, Reaman GH, Hank JA, A Phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 1995;75(12):2959-65
   PubMed Web of Science ®Google Scholar
• Kalwak K, Ussowicz M, Gorczyńska E, Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors. J Interferon Cytokine Res 2003;23(4):173-81
   PubMed Web of Science ®Google Scholar
• Zhang H, Chua KS, Guimond M, Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005;11(11):1238-43
   PubMed Web of Science ®Google Scholar
• Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002;99(11):3892-904
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sportès C, Ahmadzadeh M, IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006;29(3):313-9
   PubMed Web of Science ®Google Scholar
• Sportes C, Hakim FT, Memon SA, Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205(7):1701-14
   PubMed Web of Science ®Google Scholar
• Melchionda F, Fry TJ, Milliron MJ, Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005;115(5):1177-87
   PubMed Web of Science ®Google Scholar
• Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 2008;8(9):1295-307
   PubMed Web of Science ®Google Scholar
• Navid F, Furman WL, Fleming M, The feasibility of adjuvant interferon α-2b in children with high-risk melanoma. Cancer 2005;103(4):780-7
   PubMed Web of Science ®Google Scholar
• Merchant MS, Yang X, Melchionda F, Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004;64(22):8349-56
   PubMed Web of Science ®Google Scholar
• Seibel NL, Dinndorf PA, Bauer M, Phase I study of tumor necrosis factor-α and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study. Journal of Immunotherapy with Emphasis on Tumor Immunology 1994;16(2):125-31
   PubMed Web of Science ®Google Scholar
• Baek JH, Sohn SK, Kim DH, Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. Acta Haematologica 2007;117(2):109-14
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, de Botton S, Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21(3):453-61
   PubMed Web of Science ®Google Scholar
• Arellano ML, Langston A, Winton E, Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007;13(1):116-23
   PubMed Web of Science ®Google Scholar
• Zhang WG, Liu SH, Cao XM, A Phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6. Leuk Res 2005;29(1):3-9
   PubMed Web of Science ®Google Scholar
• Anderson PM. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999;5(9):2316-23
   PubMed Web of Science ®Google Scholar
• Rao RD. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol Cancer Clin Trials 2003;26(5):493-8
   PubMed Web of Science ®Google Scholar
• Negrier S, Michon J, Floret D, Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma published erratum appears in J Clin Oncol 1992 Jun;10(6):1026. J Clin Oncol 1991;9(8):1363-70
   PubMed Web of Science ®Google Scholar
• Casper JT, Camitta BM, McOlash L, Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a Phase I trial. J Immunother 1992;11(4):274-85
   PubMed Web of Science ®Google Scholar
• Finn O. Cancer immunology. N Engl J Med 2008;358(25):2704-15
   PubMed Web of Science ®Google Scholar
• Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother 2007;30(2):203-14
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008;180(6):3627-35
   PubMed Web of Science ®Google Scholar
• Kumar V, Halder R, Arrenberg P. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol 2009;218(2):246-50
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25(3):315-22
   PubMed Web of Science ®Google Scholar
• Mayumi O. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99(8):1501-6
   PubMed Web of Science ®Google Scholar
• Vakkila J, Jaffe R, Michelow M, Lotze MT. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clin Cancer Res 2006;12(7):2049-54
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182(8):4499-506
   PubMed Web of Science ®Google Scholar